Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Odds Ratio
100%
Peritoneal Metastasis
100%
Pelvic Metastasis
100%
Inguinal Metastasis
100%
Squamous Cell Carcinoma of Unknown Primary
100%
Comprehensive Genomic Profiling
100%
Genetic Modification
66%
SCCUP
50%
Tumor Protein p53 (TP53)
33%
Histology
33%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
33%
PIK3CA
33%
HPV Infection
33%
APOBEC mutation Signature
33%
F1CDx
33%
Pelvic Dysfunction
33%
Retroperitoneal Diseases
33%
Prostate Cancer
16%
Microsatellite Instability-high (MSI-H)
16%
Breast Cancer
16%
No Significant Difference
16%
Nodal Metastasis
16%
Occult
16%
Targeted Therapy
16%
BRCA2
16%
Viral Infection
16%
Targeted Treatment
16%
Treatment Decisions
16%
Urologic Oncology
16%
Gynecologic Oncology
16%
Fibroblast Growth Factor Receptor 3 (FGFR3)
16%
Disease Location
16%
Genomic Landscape
16%
Foundation Medicine
16%
Molecular Landscape
16%
TMPRSS2-ERG Fusion
16%
PD-L1 Expression
16%
Tumor mutational Burden
16%
Pathologists
16%
Tissue Biopsy
16%
Actionable Genomic Alterations
16%
Biomarker-guided Trials
16%
UV Light Exposure
16%
Medicine and Dentistry
Squamous Cell Carcinoma
100%
Pelvis
100%
Cancer of Unknown Primary Origin
100%
Retroperitoneal Cancer
100%
Comprehensive Genomic Profiling
100%
Odds Ratio
66%
Genetics
66%
Diseases
33%
Targeted Therapy
22%
Histology
22%
Pelvic Disease
22%
Cyclin Dependent Kinase Inhibitor 2A
22%
Cancer of Unknown Primary Site
22%
Retroperitoneal Disease
22%
Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide Like
22%
HPV Infection
22%
Biological Marker
11%
Microsatellite Instability
11%
Biopsy Technique
11%
Nodal Metastasis
11%
Clinical Trial
11%
Prostate Cancer
11%
BRCA2
11%
Virus Infection
11%
BRCA1
11%
Pathologist
11%
Ultraviolet Radiation
11%
Gynecological Oncology
11%
Fibroblast Growth Factor Receptor 3
11%
Urologic Oncology
11%
Programmed Death-Ligand 1
11%
Tumor Mutational Burden
11%
Biochemistry, Genetics and Molecular Biology
Genomics
100%
APOBEC
22%
Cyclin Dependent Kinase Inhibitor 2A
22%
Microsatellite Instability
11%
BRCA2
11%
Clinical Trial
11%
Ultraviolet Radiation
11%
BRCA1
11%
PD-L1
11%
KRAS
11%
Fibroblast Growth Factor Receptor 3
11%
TMPRSS2
11%
Light Exposure
11%
Targeted Therapy
11%